Trials / Completed
CompletedNCT02057302
A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia
A Multicenter, Pragmatic Randomized, Double-blind, Placebo-controlled Trial of Xuezhikang Capsule for Treating Dyslipidemia: a Postmarketing Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,400 (actual)
- Sponsor
- China Academy of Chinese Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Dyslipidemia contributes greatly to the formation and progression of atherosclerosis (AS), which plays a dominant role in leading to CHD. Xuezhikang is a partially purified extract of fermented red yeast rice (Monascus purpureus). It is composed of 13 kinds of natural statins, unsaturated fatty acids, ergosterol,amino acids, flavonoids, alkaloid, trace element, and so forth. Xuezhikang has been recommended in a guideline for China adult dyslipidemia prevention. This study aims to evaluate the benefit and side effect of Xuezhikang, a potential alternative drug of statins, for patients with dyslipidemia, and thus provide further evidence for clinical application.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xuezhikang capsule |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2012-12-01
- First posted
- 2014-02-07
- Last updated
- 2014-02-07
Source: ClinicalTrials.gov record NCT02057302. Inclusion in this directory is not an endorsement.